Evidence map›Paper›PMID 39939290›Full record

SynthesisFuture cardiology2025

The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Ubaid Khan, Ahmed Mazen Amin, Amira Mohamed Taha, Yehya Khlidj, Majd M AlBarakat, Mariam Elewidi, Mohamed Abuelazm, Mustafa Turkmani, Basel Abdelazeem, Rida Laeeq

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Transplant Recipients: A Systematic Review and Meta-analyses.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ubaid KhanDivision of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Ahmed Mazen AminFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Amira Mohamed TahaFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Yehya KhlidjFaculty of Medicine, University of Algiers, Algiers, Algeria.
Majd M AlBarakatFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Mariam ElewidiFaculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed AbuelazmFaculty of Medicine, Tanta University, Tanta, Egypt.
Mustafa TurkmaniFaculty of Medicine, Michigan State University, East Lansing, MI, USA.ORCID 0009-0001-4261-0638
Basel AbdelazeemDepartment of Cardiology, West Virginia University Morgantown, West Virginia, USA.
Rida LaeeqDepartment of Cardiology, West Virginia University Morgantown, West Virginia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, especially in diabetic patients. However, the cardioprotective effects of early SGLT2i administration following acute myocardial infarction (AMI) remain unclear.

objectiveThis study aims to investigate the impact of SGLT2is on clinical outcomes in patients post-AMI.

methodsA comprehensive search was conducted in PubMed, CENTRAL, WOS, Scopus, and EMBASE up to April 2024. Risk ratio (RR) was used for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI).

resultsSeven studies with 11,407 patients were included. SGLT2is did not significantly reduce the incidence of major adverse cardiovascular events (MACE) (RR = 0.94, 95% CI [0.68, 1.29],

conclusionIn post-AMI patients, SGLT2is do not significantly affect MACE or mortality but are associated with reduced heart failure risk and improved ejection fraction. PROTOCOL REGISTRATION: PROSPERO identifier number: CRD42024506806.

Indexed as

Diabetes Mellitus, Type 2Myocardial InfarctionSodium-Glucose Transporter 2 InhibitorsHumansRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 Inhibitorscardiac remodelingheart failuremortalitymyocardial infarctionSGLT2i

Identifiers

PMID39939290
PMCPMC11875467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.